147 related articles for article (PubMed ID: 23931337)
1. Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.
Pochintesta L; Mangiacavalli S; Cocito F; Pompa A; Albertini R; Pascutto C; Ferretti VV; Cazzola M; Corso A
Leuk Lymphoma; 2014 Jun; 55(6):1397-8. PubMed ID: 23931337
[No Abstract] [Full Text] [Related]
2. Optimal use of bisphosphonates in patients with multiple myeloma.
Terpos E; Roodman GD; Dimopoulos MA
Blood; 2013 Apr; 121(17):3325-8. PubMed ID: 23407550
[No Abstract] [Full Text] [Related]
3. Bisphosphonate therapy in the treatment of multiple myeloma.
Lawson MA; Ashcroft J; Croucher PI
Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
[TBL] [Abstract][Full Text] [Related]
4. [Integrated supportive therapy for multiple myeloma-bone disease treatment, myeloma kidney treatment, cryotherapy, nutrition support team].
Miwa A
Nihon Rinsho; 2012 Apr; 70 Suppl 2():603-27. PubMed ID: 23134022
[No Abstract] [Full Text] [Related]
5. Novel therapeutic targets in myeloma bone disease.
Webb SL; Edwards CM
Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110
[TBL] [Abstract][Full Text] [Related]
6. The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients.
Zhang X; Chang C; Zhao Y; Wu L; Zhang Z; Li X
Hematology; 2012 Sep; 17(5):255-60. PubMed ID: 22971530
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
Ural AU; Avcu F
Clin Cancer Res; 2007 Jun; 13(11):3432. PubMed ID: 17545554
[No Abstract] [Full Text] [Related]
8. Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy.
Kleber M; Udi J; Metzke B; Terpos E; Roodmann GD; Morgan G; Dispenzieri A; Einsele H; Wäsch R; Engelhardt M
Leuk Lymphoma; 2012 Jun; 53(6):1057-61. PubMed ID: 22149167
[TBL] [Abstract][Full Text] [Related]
9. [Management of bone lesions in multiple myeloma].
Hata H; Mitsuya H
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1072-6. PubMed ID: 16912524
[TBL] [Abstract][Full Text] [Related]
10. Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).
Sanders J; Crawford B; Gibson J; Joy Ho P; Iland H; Joshua D
Int J Lab Hematol; 2007 Oct; 29(5):395-7. PubMed ID: 17824924
[No Abstract] [Full Text] [Related]
11. Atraumatic bone pain in multiple myeloma secondary to bisphosphonate-related bone injury.
Williams R; Wolger L; Alajangi R
Br J Haematol; 2021 Jan; 192(2):229. PubMed ID: 33094837
[No Abstract] [Full Text] [Related]
12. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Yee AJ; Raje NS
Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
[TBL] [Abstract][Full Text] [Related]
13. Biochemical markers of bone turnover in diagnosis of myeloma bone disease.
Dizdar O; Barista I; Kalyoncu U; Karadag O; Hascelik G; Cila A; Pinar A; Celik I; Kars A; Tekuzman G
Am J Hematol; 2007 Mar; 82(3):185-91. PubMed ID: 17022050
[TBL] [Abstract][Full Text] [Related]
14. Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans.
Zaidi M; Epstein S; Friend K
Ann N Y Acad Sci; 2006 Apr; 1068():560-3. PubMed ID: 16831952
[TBL] [Abstract][Full Text] [Related]
15. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
Raje N; Vescio R; Montgomery CW; Badros A; Munshi N; Orlowski R; Hadala JT; Warsi G; Argonza-Aviles E; Ericson SG; Anderson KC
Clin Cancer Res; 2016 Mar; 22(6):1378-84. PubMed ID: 26644410
[TBL] [Abstract][Full Text] [Related]
16. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
17. The role of bisphosphonates in multiple myeloma.
Levy J; Roodman GD
Curr Hematol Malig Rep; 2009 Apr; 4(2):108-12. PubMed ID: 20425422
[TBL] [Abstract][Full Text] [Related]
18. The significance of carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma.
Kuliszkiewicz-Janus M; Małecki R; Zółtaszek A; Zastawny M
Leuk Lymphoma; 2005 Dec; 46(12):1749-53. PubMed ID: 16263577
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for Patients Diagnosed With Multiple Myeloma.
Mhaskar R; Djulbegovic B
JAMA; 2018 Oct; 320(14):1483-1484. PubMed ID: 30326511
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
